Julien Meissonnier
Chief Tech/Sci/R&D Officer chez CATALENT, INC.
Profil
Fondateur d'Accellix, Inc, Julien Meissonnier occupe actuellement le poste de président et directeur d'Accellix, Inc et de directeur scientifique et vice-président de Catalent, Inc, directeur scientifique de Catalent Pharma Solutions, Inc. (une filiale de Catalent, Inc.). Il a précédemment occupé les postes de président et de directeur général de Cardio Ventures Ltd, de directeur du développement commercial chez Sol-Gel Technologies Ltd, de directeur du marketing et du développement commercial chez Evogene Ltd, de directeur du marketing mondial chez Novartis AG et de directeur du marketing mondial chez Ciba-Geigy AG (une filiale de Novartis AG) et d'ingénieur en développement chez Rhône-Poulenc SA. Il a obtenu un diplôme d'études supérieures de l'université de Washington et un MBA de l'INSEAD.
Postes actifs de Julien Meissonnier
| Sociétés | Poste | Début |
|---|---|---|
| CATALENT, INC. | Chief Tech/Sci/R&D Officer | 19/11/2019 |
Accellix, Inc.
 Accellix, Inc. Medical SpecialtiesHealth Technology Accellix, Inc. develops in-vitro diagnostic systems. Its Accellix platform is an affordable tabletop diagnostic device with single-use assay cartridges that does not require extensive training nor involve complex operational processes. The firm’s product is an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test. The company was founded in 2009 by Julien Meissonnier and Harvey Kasdan and is headquartered in San Jose, CA. | Founder | 01/01/2009 |
Catalent Pharma Solutions, Inc.
 Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Chief Tech/Sci/R&D Officer | 01/10/2019 |
Anciens postes connus de Julien Meissonnier
| Sociétés | Poste | Fin |
|---|---|---|
Cardio Ventures Ltd.
 Cardio Ventures Ltd. Investment ManagersFinance Cardio Ventures Ltd is a venture capital firm. The firm headquartered in Jerusalem, Israel. | Chief Executive Officer | 01/01/2011 |
| SOL-GEL TECHNOLOGIES LTD. | Corporate Officer/Principal | - |
| NOVARTIS AG | Sales & Marketing | - |
Ciba-Geigy AG
 Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Sales & Marketing | - |
| EVOGENE LTD. | Sales & Marketing | - |
Formation de Julien Meissonnier
| University of Washington | Graduate Degree |
| INSEAD | Masters Business Admin |
| École Nationale Supérieure d'Ingénieurs de Caen | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| NOVARTIS AG | Health Technology |
| SOL-GEL TECHNOLOGIES LTD. | Health Technology |
| EVOGENE LTD. | Health Technology |
| CATALENT, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Accellix, Inc.
Accellix, Inc. Medical SpecialtiesHealth Technology Accellix, Inc. develops in-vitro diagnostic systems. Its Accellix platform is an affordable tabletop diagnostic device with single-use assay cartridges that does not require extensive training nor involve complex operational processes. The firm’s product is an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test. The company was founded in 2009 by Julien Meissonnier and Harvey Kasdan and is headquartered in San Jose, CA. | Health Technology |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
| Rhone-Poulenc SA | Process Industries |
Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. Pharmaceuticals: MajorHealth Technology Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ. | Health Technology |
Cardio Ventures Ltd.
Cardio Ventures Ltd. Investment ManagersFinance Cardio Ventures Ltd is a venture capital firm. The firm headquartered in Jerusalem, Israel. | Finance |
